Current Treatments as of March 2017

There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare.  Many of the older combinations involve the use of interferon which has many side effects. The list below is of the latest and most effective drugs for treating hepatitis C in Canada.

Although there are fewer side effects with the new drugs compared to those of earlier treatments (telaprevir, interferon), there can be serious side effects for people with underlying conditions, such as heart disease and advanced cirrhosis.

Some of the newer combinations may still require the addition of interferon and/or ribavirin depending on the severity of the disease.

Your physician and clinical nurses will guide you through what you need to know and what you need to do should you be accepted for treatment.

IMPORTANT: Eligibility for treatment under BC PharmaCare currently is that the patient have Fibrosis stage F2 or greater. But this doesn’t always get you treated since BC PharmaCare restricts how many people it treats each year due to financial constraints.

BC PharmaCare will expand access to include patients with less advanced disease (fibrosis scores of F0 or F1) if they have been diagnosed with certain co-existing factors.  All HCV patients with fibrosis scores of F2 or higher also remain eligible for reimbursement.  Starting in 2018-19, BC PharmaCare will provide coverage for any resident of the province living with chronic hepatitis C, regardless of the type or severity of their disease. (See http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-sofosbuvir-velpatasvir, for example, for the criteria for Epclusa.)

Additionally, below is the link to the BC Pharmacare newsletter which contains information regarding listing criteria for EPCLUSA as well as all other HCV medications. http://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/newsletters/news17-004.pdf

Genotypes 1a or 1b (GT1a/1b):

  • Harvoni:
    This drug combination is covered by BC Pharmacare
  • Zepatier (grazoprevir / elbasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare
  • Epclusa (sofosbuvir / velpatasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare
  • Sunpreva (asunaprevir) plus Daklinza (Daclatasvir) for GT1b:
    This drug combination is covered by BC Pharmacare
  • Holkira Pak:
    This drug combination is no longer covered by BC Pharmacare

Genotype 2:

  • Epclusa (sofosbuvir / velpatasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare
  • Sovaldi in combination with ribavirin:
    This drug combination is covered by BC Pharmacare

Genotype 3:

  • Daklinza plus Sovaldi:
    This drug combination is covered by BC Pharmacare
  • Epclusa (sofosbuvir / velpatasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare
  • Sovaldi in combination with ribavirin:
    This drug combination is covered by BC Pharmacare

Genotype 4:

  • Epclusa (sofosbuvir / velpatasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare
  • Zepatier (grazoprevir / elbasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare

Genotype 5:

  • Epclusa (sofosbuvir / velpatasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare

Genotype 6:

  • Epclusa (sofosbuvir / velpatasvir) with or without ribavirin:
    This drug combination is covered by BC Pharmacare

 

For more detailed information on the status of current HCV treatment in Canada

TREATMENT ACCESS MAP
Directions:
Click on the Province or Territory name.
Click on “HCV Medications”
Click on the name of the drug to get all the important information you need about the drug.

 

For information on HCV treatment applications and approvals in Canada click here: http://hepatitiseducation.med.ubc.ca/resources/english-resources/treatment-news/